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Abstract: Background
Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages
of Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been
established as ‘AD signature’. To what extent MRI can detect amyloid-related cerebral
changes from structural MRI in cognitively unimpaired individuals is still an area open
for exploration.
Method
Longitudinal 3D-T1 MRI scans were acquired from a subset of the ADNI cohort
comprising 403 subjects: 79 controls (Ctrls), 50 preclinical AD (PreAD), 274 MCI and
dementia due to AD (MCI/AD). Amyloid CSF was used as gold-standard measure with
established cut-offs (<192pg/mL) to establish diagnostic categories. Cognitively
unimpaired individuals were defined as Ctrls if were amyloid negative and PreAD
otherwise. The MCI/AD group was amyloid positive. Only subjects with the same
diagnostic category at baseline and follow-up visits were considered for the study.
Longitudinal morphometric analysis was performed using SPM12 to calculate Jacobian
determinant maps. Statistical analysis was carried out on these jacobian maps to
identify structural changes that were significantly different between diagnostic
categories. A machine learning classifier was applied on Jacobian determinant maps to
predict the presence of abnormal amyloid levels in cognitively unimpaired individuals.
The performance of this classifier was evaluated using receiver operating characteristic
curve analysis and as a function of the follow-up time between MRI scans. We applied
a cost function to assess the benefit of using this classifier in the triaging of individuals
in a clinical trial-recruitment setting.
Results
The optimal follow-up time for classification of Ctrls vs PreAD was Δt>2.5 years. The
longitudinal voxel-based classifier achieved an AUC=0.866 (95%CI:0.72-0.97). The
brain regions that showed the highest discriminative power to detect amyloid
abnormalities were the medial, inferior and lateral temporal lobes, precuneus, caudate
heads, basal forebrain and lateral ventricles.
Conclusions
Our work supports that machine learning applied to longitudinal brain volumetric
changes can be used to predict, with high precision, presence of amyloid abnormalities
in cognitively unimpaired subjects. Used as a triaging method to identify a fixed
number of amyloid positive individuals, this longitudinal voxelwise classifier is expected
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to avoid 55% of unnecessary CSF and/or PET scans and reduce economic cost by
40%.
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Abstract 
 
Background: Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of 
Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been established as ‘AD 
signature’. To what extent MRI can detect amyloid-related cerebral changes from structural MRI in 
cognitively unimpaired individuals is still an area open for exploration. 
Method: Longitudinal 3D-T1 MRI scans were acquired from a subset of the ADNI cohort comprising 403 
subjects: 79 controls (Ctrls), 50 preclinical AD (PreAD), 274 MCI and dementia due to AD (MCI/AD). 
Amyloid CSF was used as gold-standard measure with established cut-offs (<192pg/mL) to establish 
diagnostic categories. Cognitively unimpaired individuals were defined as Ctrls if were amyloid negative 
and PreAD otherwise. The MCI/AD group was amyloid positive. Only subjects with the same diagnostic 
category at baseline and follow-up visits were considered for the study. Longitudinal morphometric 
analysis was performed using SPM12 to calculate Jacobian determinant maps. Statistical analysis was 
carried out on these jacobian maps to identify structural changes that were significantly different between 
diagnostic categories. A machine learning classifier was applied on Jacobian determinant maps to predict 
the presence of abnormal amyloid levels in cognitively unimpaired individuals. The performance of this 
classifier was evaluated using receiver operating characteristic curve analysis and as a function of the 
follow-up time between MRI scans. We applied a cost function to assess the benefit of using this classifier 
in the triaging of individuals in a clinical trial-recruitment setting. 
Results: The optimal follow-up time for classification of Ctrls vs PreAD was Δt>2.5 years. The longitudinal 
voxel-based classifier achieved an AUC=0.866 (95%CI:0.72-0.97). The brain regions that showed the 
highest discriminative power to detect amyloid abnormalities were the medial, inferior and lateral temporal 
lobes, precuneus, caudate heads, basal forebrain and lateral ventricles. 
Conclusions: Our work supports that machine learning applied to longitudinal brain volumetric changes 
can be used to predict, with high precision, presence of amyloid abnormalities in cognitively unimpaired 
subjects. Used as a triaging method to identify a fixed number of amyloid positive individuals, this 
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longitudinal voxelwise classifier is expected to avoid 55% of unnecessary CSF and/or PET scans and 
reduce economic cost by 40%.  
 
Keywords: preclinical AD signature, Jacobian determinant, MRI, machine learning, longitudinal 
voxelwise analysis 
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1. Background 
Despite enormous efforts, there is yet no disease-modifying treatment available for Alzheimer’s disease 
(AD). In this scenario, a promising strategy aims to prevent AD by developing interventions before the 
onset of symptoms [1]. The main challenge to operationalize such strategy lies in the detection of those 
individuals who are at increased risk to develop symptoms in the short term and would best benefit from 
these interventions [2]. 
Biomarker studies have demonstrated that AD pathology unfolds as a continuum [3]. AD starts with a 
dormant asymptomatic stage - the “preclinical state”  (PreAD) - followed by the progressively impaired 
symptomatic states of mild cognitive impairment (MCI) and dementia. PreAD is characterized by 
unimpaired cognition, performance within norms taking into account age and education, and abnormal 
amyloid biomarkers as measured in cerebrospinal fluid (CSF) or by positron emission tomography (PET). 
The PreAD stage can last for decades and thus provides a window of opportunity for potential preventive 
intervention with disease-modifying therapies as long as the earliest pathophysiological changes that 
precede the emergence of AD clinical symptoms can be detected. However, CSF and PET are not 
suitable techniques for the screening or triaging of the general population given their invasiveness and 
high cost. 
Recent developments in Magnetic Resonance Imaging (MRI) permit the study of the neuroanatomy with 
unprecedented detail. MRI has proven to be instrumental at characterizing impending dementia and 
cognitive decline due to AD both for research and in the clinic [4]. The neuroimaging AD signature has 
been established as structural changes in AD-vulnerable structures (i.e. entorhinal cortex, hippocampus 
and temporal lobe) that constitute diagnostic markers of cognitive impairment and AD progression [5, 6]. 
A preclinical AD signature might also be present in structural imaging, as several recent studies point out 
[7, 8, 9, 10, 13], even though to a lower degree as what is observed in the clinical stages of the disease. 
On top of this, preliminary results by our group [13] and others [11] show that brain anatomical changes 
at the PreAD stage involve regions of the aforementioned AD signature. 
In this line, artificial intelligence, hand in hand with MRI, come to the aid of early disease detection across 
a variety of medical domains. In the scope of AD, many efforts have been dedicated to the automated 
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detection of mild-cognitive impairment and dementia due to AD based on biomarkers and MRI-T1 images 
of subjects [12]. However, the detection of PreAD from MRI datasets has received much less attention. 
In a previous study, we showed that MRI in combination with machine learning can predict amyloid 
positivity with enough accuracy to be cost-effective as a pre-screening tool [13]. In that report, the MRI’s 
predictive capacity was validated in two independent cohorts and a similar cross-sectional study achieved 
similar results in a third population [14]. In the present work, instead, we investigate how pathological 
brain structural changes in preAD and AD subjects differ from normal brain ageing processes. Our 
longitudinal voxelwise approach utilizes tensor-based morphometry to make inferences on local tissue 
gain or loss that occur over the different stages of AD. We seek to identify the most significant features 
from the Jacobian determinant maps that are characteristic of AD progression, and use these to predict 
amyloid positivity in early AD stages. 
The objectives of this work are therefore twofold. On one hand, we seek to characterize the PreAD 
signature based on a statistical analysis of Jacobian determinants across the sample population. 
Secondly, we develop a machine-learning tool to identify amyloid positive subjects through the detection 
of abnormal structural changes in their brain. This novel classification model relies on longitudinal MRI 
images acquired throughout two time points, and is able to predict amyloid positivity based solely on 
brain structural changes that are different to those that pertain to normal brain ageing as shown in 
cognitively unimpaired and amyloid negative individuals used as controls.  
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2. Methods 
2.1 Subjects 
Subjects for this study were selected from the ADNI database [15] provided that they had two or more 
longitudinal 3D-T1 MRI acquisitions and cerebrospinal fluid (CSF) biomarker data publicly available. 
Subjects were assigned biomarker-assisted diagnostic categories following recently published guidelines 
[16]. Subjects labelled as ‘Normal’ in ADNI were classified as amyloid negative cognitively unimpaired 
(Ctrl) if CSF Aβ was above 192 pg/mL and preclinical (PreAD) if CSF Aβ was below 192 pg/mL. This 
threshold has been shown to optimally discriminate between cognitively unimpaired individuals and AD 
patients, and has been extensively used as cutoff value for amyloid positivity [17]. Subjects were 
categorized as MCI or AD according to the ADNI diagnostic categories reported in [18] and we selected 
only those individuals with CSF Aβ levels below 192 pg/mL to exclude subjects harboring non-AD 
pathological changes. At baseline, this diagnostic algorithm yielded 79 Ctrl, 50 PreAD and 274 
MCI/dementia due to AD, a total of 403 subjects with complete imaging and CSF data. As an additional 
inclusion criteria, in follow-up visits, all subjects remain in the same diagnostic category. 
2.2 MRI data 
Structural 3D-T1 MRI images were acquired across different scanners and institutions. Each image was 
associated with a cognition score and a set of CSF biomarker values (amyloid-beta, total tau and 
phosphorylated tau). The date of the CSF extraction was selected to be within 90 days from the date of 
the MRI scan. Each subject had at least one follow-up visit with the corresponding T1-MRI image, 
cognition score and CSF biomarker values. The number of visits may differ across subjects (Table 1). 
The total number of MRI scans analyzed was 980. The time interval between visits was, at least, 6 months 
apart. 
2.2.1 Image Analysis 
The SPM12 [19] neuroimaging software suit was used for every step of this longitudinal analysis pipeline. 
All image pairs corresponding to the same subject from the ADNI database were processed with 
longitudinal pairwise registration. Images in each pair were averaged and their respective Jacobian 
determinant was calculated, which reflects the regional cerebral volumetric changes between the 
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respective time-points. DARTEL normalization [33] was applied onto average images to normalize 
Jacobian determinant maps to MNI space [34] and allow comparison across subjects. The intensity of 
each voxel in the Jacobian image was normalized by the interval of time between reference and follow-
up visits (i.e. Δt ). The number of Jacobian determinant maps for each subject’s diagnostic category is: 
184 Ctrl, 114 PreAD and 543 MCI/AD. 
On top of the voxelwise analysis, a regional analysis was also performed. To this end, regions of interest 
(ROIs) in the AAL atlas were masked by each subject’s grey matter segmentation and the mean value of 
the remaining voxels’ intensity per region was computed [20].   
2.3 Automated recognition of PreAD volumetric changes using machine learning 
All Jacobian determinant maps from each subject were labeled using subject’s label (i.e. PreAD, Ctrl), 
leaving a study cohort of N = 129 (NCtrl = 79, NPreAD = 50). Importantly, as mentioned before, we only 
consider pairs of images for which no transitions have been observed across categories.  This analysis 
was performed only on the PreAD and Ctrl subjects. 
Feature selection 
Due to the limited sample size and high-dimensionality of the Jacobian determinant maps, we perform 
feature selection to keep an optimal percentage of the most relevant features. To this end, we use a filter 
feature selection method based on F-test, taking into consideration Jacobian features and subject labels. 
The F-test metric is used to create a ranking of all Jacobian features and finally a fixed percentage of the 
highly ranked features are used for classification [22]. 
Classification and performance evaluation 
Ridge logistic regression with hyperparameter C [23] is used for binary classification of Jacobian features 
within the nested cross-validation (CV) framework [24] defined in Figure 1. It consists of an inner CV loop 
for model selection and an outer CV loop for assessing model performance. First, in the outer loop, 
subjects are randomly divided into 80% train set and 20% test set previously fixing a prevalence of 
interest (the percentage of samples of the amyloid positive class). For each subject in either set, all 
available Jacobian determinant maps are used for classification. The train set is used for feature selection 
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and model optimization while the test set is left out for final model evaluation. The random split by subject 
ensures that there is no contamination of the test set with Jacobian determinants of the train set.  
Feature selection is computed using only the train set. In the model optimization step, the train set is 
further split into sub-train (2/3) and validation (1/3) sets using a (k=3)-fold cross-validation. A grid search 
strategy is used to optimize the classifier hyperparameter C by maximizing the f1-score on the validation 
set. Finally, the model is estimated using the optimized hyperparameter C on the whole train set. Then, 
the model is applied to the test set to compute standard performance metrics (i.e. area under the receiver 
operating curve (AUC), accuracy, precision, sensitivity, specificity and f1-score). Following the 
formulation in [13], we also report the reduction of economic cost (i.e. savings) of using this classification 
framework as a tool for AD screening.  
This procedure is repeated n=100 times and performance results are reported using the average and 
standard deviation. The overall implementation is based on the scikit-learn Python library, (version 0.18) 
[25]. 
Savings  
Savings in a triaging process were calculated as the percentage difference in resources between the 
standard recruitment protocol and using our proposed protocol in [13] to obtain a desired number of 
PreAD subjects for the clinical study. Savings were assessed in terms of economic cost [Eq. 1] or 
participant burden [Eq. 2], i.e. the amount of unnecessary PET/CSF tests spared through MRI-
screening.  
Eq. [1]    𝑆𝑎𝑣𝑖𝑛𝑔𝑠𝐶𝑂𝑆𝑇  =  1 − 
1
2·𝐶𝑎𝑣𝑔
(𝜌
𝐶𝑃𝐸𝑇
𝑃
+
𝐶𝑀𝑅𝐼
𝑅
)  
Eq. [2]  𝑆𝑎𝑣𝑖𝑛𝑔𝑠𝐶𝑆𝐹/𝑃𝐸𝑇 = 1 − 𝜌 
1
𝑃
 
Savings rely on the algorithmic precision (P) and recall/sensitivity (R) and on the prevalence of the 
population (ρ). The costs of MRI and PET were estimated as CMRI = 700€, and CCSF = 3000€ and Cavg 
represents the average cost among the screening tests which may include additional costs (e.g. 
neuropsychological cognitive testing). 
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2.4 Statistical Analysis 
The aim of the statistical analysis is to identify significant group differences in brain volumetric change 
rate between AD stages. We will investigate the location of these stage-specific changes, and whether 
they represent a volume increase (positive changes) or decrease (negative changes). Every Jacobian 
determinant map is treated as an independent variable. 
Two-sample t-test: Statistical analyses were performed by comparing any combination of two subject 
categories. The uncorrected threshold for statistical significance was p < 0.005. Spatial clustering of 
regions with statistically relevant voxels was applied to rule out false-positives, with a clustering threshold 
of k > 100 voxels under which voxel clusters with smaller sizes were discarded.  
Data normalization: The effects of normal ageing on brain structural changes was considered as a 
confounder and regressed out [21]. Coefficients for linear regression on age were fitted using only Ctrls 
(i.e. individuals that are amyloid negative, asymptomatic in all visits). 
The age corresponding to each Jacobian determinant was defined as the mean age between the two 
visits i.e. age =  (agereference + agefollow-up)/2. 
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3. Results 
3.1.- Demographic and follow-up comparisons 
We included a total of 430 subjects at baseline with at least one follow-up visit over three categories: 
Ctrl (n=79), PreAD (n=50) and MCI/AD (n=274). Demographic data and follow-up period is presented in 
Table 2 split into different categories. 
We denote as Δt the time interval between two follow-up visits (i.e. reference and target images). 
The distribution of the time interval (Δt) between follow-up visits on all subjects is given in Figure 2. The 
median of the distribution is 2.01 years. 
3.2 Machine learning 
We use machine learning for voxelwise prediction of amyloid positive subjects (PreAD) among cognitively 
unimpaired subjects. A realistic prevalence for PreAD subjects on middle-age adults is 20% [26]. We use 
this prevalence to fix the proportion of PreAD on the test set on all machine learning experiments. 
Another key parameter of the analysis is the temporal distance (Δt) between reference and target images 
used to compute the Jacobian determinant maps. In Figure 3 we report the performance of the classifier 
as a function of minimal Δt values in the test set. It is observed that even though we normalize each 
Jacobian determinant map with respect to the Δt parameter, the preclinical signature is within the 
detection range when visits are at least 2.5 years apart. In the case in which Δt > 2.5 years, the 
performance of the classifier based on structural changes is much better than a classifier trained on 
individual images as reported in our previous cross-sectional study that reports an AUC = 0.76 [13]. When 
using Jacobian determinant maps with smaller temporal distance (Δt < 2.5 years), the mean performance 
is worse than the cross-sectional analysis, probably due to the low signal to noise ratio between the 
changes due to normal brain ageing and the changes due to amyloid positivity [13].  
The optimal temporal span in terms of AUC and savings between data acquisitions is Δt > 2.5 years. The 
number of subjects with follow-up visits between 2.5 < Δt < 3.5 years from baseline is reduced to 18 Ctrls, 
10 PreAD and 39 MCI/AD subjects with 25, 16 and 52 Jacobian determinant maps respectively. In what 
follows, throughout the paper, we use only Jacobian determinant maps within the optimal temporal span 
(2.5 < Δt < 3.5 years). 
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Receiver operating characteristic curve (ROC) and precision-recall (PR) curves of the classifier are 
shown in Figure 4. A savings heatmap that responds to Eq. 1 is overlaid on the PR curve, while the mean 
and standard deviation of the model performance are plotted against the random classifier on the ROC 
curve.  
The impact of different number of features used to train our multivariate algorithm is presented in Table 
3, evaluated on our dataset which is imbalanced (36% of preclinical subjects). Note that the prevalence 
of preclinical subjects on the test set is forced to 20% using permutations. When using a low number of 
features, the model underrepresents the preclinical signature, not being able to capture all data 
heterogeneity. In contrast, when using a high number of features, the model is not able to generalize 
results to unseen Jacobian determinant maps, overfitting the development set. Hence, the best results 
are obtained using a moderate number of features that are able to both represent the preclinical signature 
and still generalize well to the test set.  
An optimal compromised solution between several metrics is to design our model using a 0.5% of the 
total Jacobian features. In this case, after the 100 iterations of the nested cross-validation framework, a 
heatmap of selected features is shown in Figure 5. As expected, the top selected features correspond to 
typical regions affected by AD pathology like the caudates, fusiform or parahippocampal gyrus, 
presenting high overlap with the statistical analysis presented in the next section. This result shows that 
a machine learning classifier trained on changes in specific brain regions has the capacity to predict the 
presence of early amyloid pathology in asymptomatic individuals as measured by MRI. 
3.3. Statistical analysis: 
In parallel to the machine learning classification model, we carried out a voxel-wise statistical analysis 
using the full dataset of Jacobian determinant maps to identify the regions of volumetric change that are 
statistically significant between the different categories Ctrl, PreAD and AD/MCI (Figure 6).  
3.3.1 Preclinical signature  
Stable PreAD individuals show significantly higher grey-matter (GM) atrophy in the parahippocampal and 
fusiform gyri as compared to amyloid negative cognitively unimpaired subjects, as shown on the left hand 
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side of Figure 6. Apparent mild GM increments are detected in the caudate heads, probably as a 
surrogate effect of ventricular expansion.  
Furthermore, comparison of longitudinal volumetric changes between amyloid negative cognitively 
unimpaired subjects and stable symptomatic ones (amyloid positive MCI or AD subjects) reveals the well-
known AD signature involving temporo-parietal and posterior cingulate areas, as well as most of the basal 
ganglia [27], as shown on the right hand side of Figure 6. Of note, apparent GM increments are also 
detected in periventricular areas, including the caudates and medial thalamus. 
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4. Discussion 
The goal of this work was to assess whether brain structural changes captured by subsequent magnetic 
resonance images can indicate the presence of abnormal amyloid levels in cognitively unimpaired 
subjects using machine learning-techniques. In addition, we also aimed at characterizing the preclinical 
signature voxelwise using Jacobian determinant maps as a measure of volumetric rate of change. 
A machine learning framework was implemented for the classification of amyloid positive subjects using 
Jacobian determinant maps as features for classification. The best achieved performance in our 
longitudinal classifier (AUC: 0.866) significantly improved the performance we previously reported for a 
cross-sectional classifier (AUC 0.76) [13]. This performance is significantly higher than what was reported 
in previous works that, on top of using MRI ROI data, built classifiers adding demographics (AUC: 0.63), 
demographics and genetics (AUC: 0.62-0.66) and demographics, neuropsychology and APOE (AUC: 
0.74) [14, 28]. Therefore, there is still room for improvement in the performance of our classifier by adding 
complementary information such as demographics and genetic risk factors.  
The increased performance of our classifier may be accounted for two factors. On the one hand and 
unlike similar previously reported classifiers, we used voxelwise data as features. Coupled with an 
efficient feature selection strategy, this allowed the classifier to select the most discriminant brain regions, 
independent of a-priori cortical parcellations. These regions mostly included AD-related areas in the 
medial and inferior temporal lobe, as well as the lateral ventricles which can be considered as the 
preclinical AD signature. On the other hand, we used subsequent images that correspond to the same 
individuals, thus eliminating an important percentage of the between-subject variability present in cross-
sectional setups.  
In this regard, we observed that our classifier works significantly better only when the pairs of MRI scans 
that are used for test and training sets are acquired more than 2.5 years apart. This time period is likely 
related to the protracted evolution of the neuroanatomical changes in preclinical AD stages. At more 
advanced stages of the disease, more rapid evolution of brain structural changes is expected, and thus, 
the benefits of a longitudinal classifier would potentially be evident with shorter time intervals. It remains 
to be explored how these promising results would be affected by the use of different scanners. 
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The predictive capacity achieved by this classifier does not place this method as substitute of gold-
standard tests to detect amyloid abnormalities. Still, if used for triaging of subjects,  e.g. clinical trial 
recruitment, we demonstrated that it could allow significant savings in terms of the number of costly gold-
standard tests that would have to be performed to detect a fixed number of amyloid positive, cognitively 
healthy subjects. Used in this way, in a cognitively unimpaired population with a prevalence of amyloid 
positivity of 20%, the accuracy of the longitudinal classifier would allow a reduction of up to 55% of 
unnecessary PET or CSF tests, which translates to a 40% reduction of the total cost, according to the 
savings model we previously proposed [13]. Nevertheless, in a clinical trial recruitment setting, it can be 
more advantageous instead to optimize the sensitivity of the classifier to maximize the number of detected 
at-risk individuals, at the cost of a slightly poorer specificity which might decrease these cost savings.  
Due to the limited sample size for training and the large inter-subject variability of cerebral morphology, 
we use a simple but effective model for prediction of amyloid positivity. Our method is fully automatic 
from feature extraction and signature learning to classification. However, the presence of high-
dimensional and low informative features together with the overlap between normal aging and AD 
processes in the brain, reduces the overall precision of the system. To account for that, future efforts will 
need larger longitudinal datasets and many initiatives are contributing to achieve this [14,29].  
On top of this, given the limited sample size and the large amount of features used for classification 
(voxels), we might have incurred in an overfitting of the existing data, potentially resulting in an 
overestimation of the capacity of the classifier. Therefore, our results need to be validated on  
independent datasets, but the scarcity of longitudinal MRI datasets with CSF biomarker levels has 
prevented us to conduct such validation in this work. Still, in our previous ROI-based study, we 
successfully validated a very similar classifier with two independent datasets without a major loss of the 
classifier’s performance [13]. 
To further characterize the preclinical AD signature, a statistical analysis was conducted and we report 
longitudinal morphological changes in cognitively unimpaired subjects with abnormal amyloid CSF levels. 
This preclinical AD signature comprises atrophy of the parahippocampal and fusiform gyri and expansion 
of the lateral ventricles. This pattern is in line with previous reports of longitudinal volumetric changes 
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associated to the presence of abnormal amyloid levels from ADNI participants that have been replicated 
in an independent cohort [30]. On the other hand, expansion of the caudate heads falls beyond this 
known pattern. Being in the proximity of the lateral ventricles, it may be questioned whether the detected 
increase in the volume of the caudates is an actual feature associated to preclinical AD stages or an 
artifact of the processing methodology to detect volumetric changes. By smoothing spatially continuous 
Jacobian determinant maps, it could be considered that the observed increase in caudate volumes could 
be a side effect of the ‘spillover’ of the Jacobian determinant maps due to the expansion of the ventricles. 
To address this question, we performed a post-hoc analysis of the caudate volumes between the Ctrls 
and PreAD groups, but using the longitudinal Freesurfer pipeline to compute change in caudate volumes. 
Since the subcortical segmentation implemented in Freesurfer uses an ROI-approach based on a 
probabilistic atlas [31], it can be considered to be virtually free from the potential ‘spillover’ effect of 
continuous Jacobian determinant maps. Results show that the changes in caudate volumes is not 
significantly different between Ctrls and PreAD individuals (p > 0.3) and, thus, it can be concluded that 
the observed caudate head expansion is artifactual and secondary to ventricular expansion. Still, this 
signal might contribute to the detection of the presence of amyloid-burden in cognitively unimpaired 
individuals.  
This study has some limitations. Even though data comes from a heterogeneous sample with different 
sites, and MRI scanners, the MRI acquisition was harmonized according the ADNI protocol. Therefore,  
the performance of our method when applied to MRI samples using different acquisition protocols may 
deviate from what is here reported. Actually, the ultimate validation of the generalizability of the results 
here reported can only be accomplished by applying the method here developed to an independent 
sample. In our previous work, the performance of a similar cross-sectional classifier was kept stable when 
derived and validated in two independent cohorts. Therefore, it can be expected the same behaviour in 
this longitudinal extension of the classifier. Finally, we used CSF amyloid as the gold-standard for amyloid 
positivity and not PET imaging. It could be argued that the performance of the classifier could be sensitive 
the the selection of the gold-standard method. However, the agreement between CSF and PET 
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determinations of amyloid is very high, particularly in the intermediate ranges where thresholds for 
positivity typically lie. 
To sum up, we here presented a machine learning framework used to predict the presence of amyloid 
abnormalities in cognitively unimpaired individuals with a moderate-to-high accuracy (AUC: 0.857) when 
MRI scans acquired 2.5 years apart are available. This performance translates to improvements of up to 
55% in the number of necessary CSF/PET tests and a reduction of 40% of the costs to detect a fixed 
number of amyloid positive individuals. This performance is expected to still have room for improvement 
by including demographic, genetic and cognitive data to the classifier. We further compare the features 
used by the classifier with the characteristic pattern of longitudinal morphological changes in preclinical 
AD that is expressed in typical AD-related regions, uncovering areas that appear to be specific to the 
preclinical AD stage. 
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5. Conclusions 
In this study, we used longitudinal structural brain MRI scans to predict the presence of amyloid pathology 
in cognitively unimpaired individuals and unveil the preclinical AD signature. We applied machine learning 
techniques on Jacobian determinant maps coding longitudinal volumetric changes at the voxel level. This 
allowed the classifier to significantly improve its performance (AUC = 0.857) with respect to previous 
cross-sectional ROI-based approximations. Areas showing the most discriminant capacity included 
medial, inferior and lateral temporal regions, along with the ventricles and caudate heads. The volumetric 
changes in these areas are in line of those observed in symptomatic stages, but are expressed to a lower 
extent. Even though the performance of the classifier does not allow for it to substitute gold-standard 
methods to determine the presence of amyloid pathology, its use as triaging tool would lead to significant 
reductions of 55% of unnecessary gold-standard tests and of 40% of the cost to detect a fixed number of 
cognitively healthy individuals in preclinical AD stages. High overlap by the features used by the classifier 
and the preclinical AD signature is found, characterized by parahippocampal and fusiform gyri atrophy 
and expansion of the ventricles. To sum up, machine learning over brain longitudinal MRI data can 
represent a valuable tool for the implementation of secondary prevention trials. 
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FIGURE LEGENDS 
 
Figure 1: Workflow of the optimization and evaluation of the classification method. The performance of 
the final classifier is evaluated on a fresh test set that has not been used for training. 
 
Figure 2: Distribution of the interval Δt between reference and follow-up visits across the whole dataset. 
 
Figure 3.  AUC and savings (blue, green) reported using Jacobian determinant maps with different time 
intervals (Δt) between reference and target and a fixed prevalence of 20% amyloid positive subjects on 
the test set. To compute savings we used optimal precision and recall values plotted in dashed orange 
and red lines, respectively using the cost function defined in Eq. 1. 
 
Figure 4. ROC and PR curves for Jacobian determinant maps with time spans in the range  2.5 < Δt < 
3.5 years using 0.5% of the features. On the left, the ROC curve is averaged across different 
development/test splits: the mean curve (blue) with the standard deviation (gray) and the curve of a 
random classifier (red). On the right, the PR curve of the classifier (blue) is overlaid on a savings heatmap 
(Eq. 1). Black lines indicate points of equal savings. 
 
Figure 5. Normalized feature maps of the 0.5% of features selected during the 100 different splits of the 
development/test sets, representing the frequency of selection of each feature. Those features have 
optimal capacity to detect the presence of early amyloid pathology in asymptomatic individuals. 
 
Figure 6: Statistical maps for group comparison between Ctrl and PreAD (PreAD signature) and Ctrl 
and MCI/AD (AD signature) subjects. Statistical significance was set to uncorrected p-value < 0.005 
and minimum spatial extent k > 100. 
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Number of visits   N 
2 295 
3 63 
4 27 
5 15 
6 3 
Total 403 subjects 
841 Jacobian maps 
 
 
Table 1: Distribution of the number of 3D-T1 MRI acquisitions per subject. 
 
Table 1 Click here to access/download;Table;Petrone_Table1.docx
  
Category  Ctrl (A𝛽-) PreAD 
(A𝛽+) 
MCI (A𝛽+) AD (A𝛽+) MCI/AD (A𝛽+) 
Number of subjects 79 50 196 78 274 
Age (years) at 
baseline (mean; std) 
73.97 (5.97) 76.04 (6.25) 73.55 (6.55) 75.44 (7.37) 74.1 (6.85) 
Sex (F/M) 37/42 21/29 79/117 33/45 112/162 
Follow-up (years) 
period (mean; std) 
2.48 (1.38) 2.32 (1.32) 2.2 (1.09) 1.4 (0.46) 1.97 (1.02) 
 
 
Table 2. Dataset demographics at baseline. 
 
Table 2 Click here to access/download;Table;Petrone_Table2.docx
  
#features (%) AUC 
(95% CI) 
Accuracy 
(95% CI) 
Precision 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Fscore  
(95% CI) 
6 
(0.001) 
0.782 (0.5-
0.99) 
0.568 
 (0.2-0.8) 
0.334 
(0.13-0.5) 
0.907 (0.33-
1.0) 
0.483 (0-
0.75) 
0.477 (0.19-
0.67) 
65 
(0.01) 
0.809  (0.6-
0.97) 
0.631 (0.27-
0.73) 
0.347 (0.18-
0.43) 
0.91 (0.33-
1.0) 
0562 (0.12-
0.75) 
0.499  
(0.28-0.6) 
653 
(0.1) 
0.846 (0.67-
1.0) 
0.651 (0.53-
0.8) 
0.368 (0.27-
0.5) 
0.97 (0.67-
1.0) 
0.571 (0.42-
0.75) 
0.531 (0.38-
0.67) 
1633 
(0.25) 
0.857 (0.72-
1.0) 
0.648 (0.46-
0.8) 
0.37 (0.27-
0.5) 
0.98 (0.67-
1.0) 
0.534 (0.33-
0.75) 
0.533 (0.43-
0.67) 
3266 
(0.5) 
0.857 
 (0.71-0.97) 
0.641 (0.46-
0.8) 
0.364 (0.26-
0.5) 
0.973 (0.67-
1.0) 
0.558 (0.33-
0.75) 
0.526 (0.38-
0.67) 
6532 
(1) 
0.866 (0.72-
0.97) 
0.653 (0.53-
0.8) 
0.363 (0.25-
0.5) 
0.933 (0.67-
1.0) 
0.583 (0.42-
0.75) 
0.521 (0.36-
0.67) 
13064 
(2) 
0.855 (0.64-
1.0) 
0.645 (0.46-
0.8) 
0.359 (0.2-
0.5) 
0.917 (0.67-
1.0) 
0.577  
(0.33-0.75) 
0.512 (0.31-
0.67) 
32661 
(5) 
0.802 (0.49-
1.0) 
0.57  
(0.4-0.77) 
0.301 (0.14-
0.47) 
0.837 (0.33-
1.0) 
0.503 
 (0.33-0.71) 
0.442 (0.33-
0.71) 
65323 
(10) 
0.77 (0.4-1.0) 0.573 (0.4-
0.77) 
0.298 (0.14-
0.47) 
0.813 (0.33-
1.0) 
0.512  
(0.33-0.75) 
0.434 (0.33-
0.75) 
 
 
Table 3. Performance of the system using a different number of features evaluated on the 
interval Δt > 2.5 years 
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(a) ROC curve            (b) Precision-Recall curve 
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